期刊
NATIONAL SCIENCE REVIEW
卷 2, 期 3, 页码 296-313出版社
OXFORD UNIV PRESS
DOI: 10.1093/nsr/nwv044
关键词
HBV; cccDNA; HBsAg; persistence; antiviral targets
资金
- National Key Basic Research Program of China [2012CB519005]
- Twelfth Five-Year National Key Technology Research and Development Programs of China [2012ZX10002007]
- National Natural Science Foundation of China [81461130019]
- German Research Foundation [SFB/Transregio TRR60]
- China Postdoctoral Science Foundation [2015T80398, 2014M551325]
Hepatitis B virus (HBV), a small DNA virus with a unique replication mode, can cause chronic hepatitis (CHB), which is characterized by the persistence of the viral covalently closed circular DNA that serves as the template for HBV replication and the production of large amounts of secreted HBV surface antigen (HBsAg) that is present in excess of the levels of infectious virus. Despite the success of currently approved antiviral treatments for CHB patients, including interferon and nucleotide analogs, which suppress HBV replication and reduce the risk of CHB-related liver diseases, these therapies fail to eradicate the virus in most of the patients. With the development of the cell and animal models for HBV study, a better understanding of the HBV life cycle has been achieved and a series of novel antiviral strategies that target different stages of HBV replication have been designed to overcome the viral factors that contribute to HBV persistence. Such basic HBV research advancements and therapeutic developments are the subject of this review.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据